Recombinant factor VIII liposomal - Opperbas/Omri

Drug Profile

Recombinant factor VIII liposomal - Opperbas/Omri

Alternative Names: F VIII liposomal - Opperbas/Omri; Factor VIII liposomal - Opperbas/Omri; Recombinant F VIII liposomal - Opperbas/Omri

Latest Information Update: 03 Feb 2011

Price : $50

At a glance

  • Originator Omri Laboratories; Opperbas Holding
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 01 Jun 2004 Phase-II clinical trials in Haemophilia A in Europe (IV)
  • 01 Jun 2004 A phase I/II trial has been completed for Haemophilia A
  • 01 Jun 2004 Factor VIII liposomal is available for licensing (http://www.omrilaboratories.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top